Avricore Health Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avricore Health Inc. Avricore Health Inc. develops and commercializes point-of-care health technologies and data management platforms for community pharmacies; its flagship HealthTab platform integrates lab-accurate testing devices with a secure cloud-based system for real-time biomarker screening, including HbA1c, lipid profiles, eGFR for chronic disease management such as diabetes and cardiovascular conditions, alongside capabilities for bacterial and viral tests like strep and COVID-19; revenue derives from equipment leasing, consumables sales, direct access testing, disease prevention programs, sponsored health initiatives, decentralized clinical trials, real-world data sets, and API integrations for third-party apps. The company operates primarily in Canada through partnerships with major chains including Shoppers Drug Mart and Rexall, and pursues international expansion in the United Kingdom and Europe via NHS-backed projects such as pharmacy-led cardiovascular screening in North East and North Central London, collaborations with UCL Partners, Barts Heart Centre, HEART UK, and Patient Knows Best for seamless data integration into 4.8 million NHS patient records. Founded in 1996 and headquartered in Vancouver, British Columbia, Avricore Health focuses on empowering pharmacists in primary care delivery while enabling patient-driven health monitoring. Recent developments include a master agreement in 2024 to pilot HealthTab with Abbott's Afinion2 analyzers at eleven Shoppers Drug Mart locations for enhanced diabetes detection; expansion of cholesterol testing to UK pharmacies with local health authority support; integration advancements with PKB for interoperability; and positioning for 2025 growth through new diagnostic device pilots, national pharmacy chain programs, and UK/Europe market scaling following record 2024 revenues.
Avricore Health Closes $1.254 Million Financing
Avricore Health Announces $1.25 Million Financing
Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab™ Platform
HealthTab™ to Expand Across North East London
Avricore Grants Options
Avricore Appoints Rodger Seccombe as CEO
AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report
AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track
HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK
Avricore Health Corporate Update: Effective Plan, Resources Result in Success
Avricore Health Refocuses Strategy to Unlock Growth Potential
Avricore Health Recognized in Deloitte's 2024 Technology Fast 50™ Companies to Watch
Avricore Grants Options
Avricore Health Corporate Update: Mid-Year Results Show Strong Growth, Profitability
Avricore Health passes major milestone as it moves into profitability
Avricore Health announces strong full-year financial and strategic growth
Avricore Health Corporate Update and Audited Results for 2023
HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations
Avricore Health seeing strong growth in 3Q with widespread HealthTab availability
Avricore Health Corporate Update – Company Demonstrates Strong Growth